drugset / Trial / NCT06533722
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer.
Timeline
- Start
- 2024-08-04
- Primary completion
- 2024-09-20
- Completion
- 2025-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |